Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1a R155K, genotype 1b D168V and genotype 1a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
本发明的化合物是含有酰基磺酰胺基团的大环肽类似物,在对于该类别的
NS3蛋白酶含有临床相关的耐药突变,如
基因型1a R155K、
基因型1b D168V和
基因型1a D168V耐药突变时,仍然保持良好的活性。本发明的化合物可用作HCV
蛋白酶的
抑制剂,用于治疗丙型肝炎病毒感染。